Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 - DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma

The Key Spinal Cord Injury Companies in the market include - Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others.

DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Spinal Cord Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinal Cord Injury Market Forecast [https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Spinal Cord Injury Market Report:

*
The Spinal Cord Injury market size in the 7MM is projected to expand from USD 354 million in 2025 to USD 1,456 million by 2034, reflecting a robust CAGR of 15.4% across major markets, including the US, EU4, UK, and Japan.

*
In January 2026, The Christopher & Dana Reeve Foundation, in collaboration with Spinal Research, has announced $1.5 million in grant funding to support four preclinical research projects focused on developing novel therapies for traumatic spinal cord injury (SCI). These studies explore new and repurposed drugs, biologics, and gene therapies designed to protect neurons, stimulate regeneration, and enhance functional recovery. One of the key obstacles to advancing SCI treatments is the funding gap between early-stage scientific discoveries and the later preclinical studies required before seeking regulatory approval from the FDA or other authorities to initiate human clinical trials.

*
In November 2025, ONWARD Medical N.V. (Euronext: ONWD; US ADR: ONWRY), a neurotechnology leader developing innovative therapies to help restore movement, function, and independence in individuals with spinal cord injury (SCI) and other mobility impairments, announced that it has received 510(k) clearance to broaden the ARC-EX System's indication for home use in the United States. The US Food and Drug Administration (FDA) has authorized the ARC-EX System for use alongside functional task-based therapy in clinical settings and prescribed at-home exercise programs, aimed at improving hand strength and sensory function in adults with chronic, non-progressive neurological impairments caused by incomplete SCI (C2-C8). The ARC-EX System is a non-invasive device that delivers programmed transcutaneous electrical stimulation to the spinal cord and is designed for operation by rehabilitation professionals in medical facilities, as well as by patients or caregivers in the home environment when appropriate.

*
In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. announced that its off-the-shelf, allogeneic iPSC-derived neural regenerative cell therapy has received approval from both China's National Medical Products Administration (NMPA) and U.S. regulators. In addition, the company has submitted a Phase I clinical trial application to the U.S. Food and Drug Administration (FDA) to evaluate the therapy for the treatment of spinal cord injury (SCI) , a currently untreatable central nervous system disorder affecting more than 15 million people globally.

*
In May 2025, A major shift in the treatment of spinal injuries emerged, marked by the approval of the world's first regenerative cell therapy for a registrational Phase I clinical trial. This historic development has the potential to address a condition long considered incurable. The US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) have authorized the global clinical study for spinal cord injury (SCI), a disorder estimated to affect more than 15 million people worldwide. SCI affects individuals across all demographics and is most commonly caused by road traffic accidents, sports-related injuries, severe falls, and workplace trauma.

*
In June 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company focused on developing innovative allogeneic ("off-the-shelf") cell therapies for severe neurological and ophthalmic disorders, announced the addition of new presenters for the 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS). This year's event will be entirely virtual, featuring interactive and on-demand sessions beginning on June 27, 2025.

*
In March 2025, Cellino and Matricelf (TASE: MTLF) announced a partnership aimed at advancing the global biomanufacturing of personalized spinal cord injury therapies. This collaboration integrates Cellino's Nebula Trademark technology with Matricelf's innovative regenerative medicine approach. By combining Cellino's automated production of induced pluripotent stem cells (iPSCs) with Matricelf's double autologous 3D differentiation process, the partnership seeks to enable scalable and patient-specific regenerative treatments. Cellino's Nebula Trademark , a proprietary closed-cassette biomanufacturing platform, is specifically designed to generate high-quality iPSCs with exceptional consistency and sterility at a large scale.

*
In March 2025, NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) announced the successful completion of a key preclinical study supporting its upcoming Investigational New Drug (IND) application. This study marks a significant step toward the company's first-in-human trials. The results demonstrated that ExoPTEN treatment, across various dosing regimens, promoted motor function recovery and notably enhanced blood flow at the spinal cord injury site both critical factors for tissue repair and functional improvement.

*
In February 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company developing allogeneic cell therapies for severe neurological disorders, announced the launch of its DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. This study aims to assess the safety and performance of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a new device designed to precisely deliver OPC1, an investigational allogeneic stem cell-based therapy, directly to the spinal cord injury site. OPC1 consists of oligodendrocyte progenitor cells and other related glial cells intended to promote spinal cord repair.

*
In February 2025, A pilot clinical trial suggests that spinal cord stimulation (SCS) may help reactivate dormant motor neurons and enhance leg muscle strength in individuals with spinal muscular atrophy (SMA). Researchers from the University of Pittsburgh School of Medicine conducted the study (NCT05430113), utilizing Medtronic's Vectris SureScan device in three SMA patients. After three months of treatment, all participants showed an improvement of at least 20 meters in the six-minute walk test (6MWT), an indicator used to assess muscle endurance and fatigue.

*
As per the World Health Organization (WHO) in 2024, there are more than 15 million individuals worldwide living with spinal cord injuries.

*
According to Bennett et al. (2022), there are around 17,000 fresh incidents of spinal cord injury (SCI) reported annually in the United States, with an estimated 282,000 individuals living with SCI.

*
The projected number of identified cases of Spinal Cord Injury across the 7MM (Seven Major Markets) was roughly 725k cases in 2022, with an anticipated rise anticipated during the forecasted period from 2022 to 2032.

*
According to the National Spinal Cord Injury Statistical Center (NSCISC) (2024), the yearly occurrence rate of traumatic spinal cord injury (tSCI) stands at roughly 54 cases per one million individuals in the United States. This equates to approximately 18,000 new tSCI incidents annually.

*
The estimated number of diagnosed Spinal Cord Injury cases in the US in 2022 stood at approximately 326k with an anticipated rise projected during the forecasted period.

*
Key Spinal Cord Injury Companies: Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others

*
Key Spinal Cord Injury Therapies: Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, and others

*
The Spinal Cord Injury epidemiology based on gender analyzed that Males are affected more as compared to females, in case of Spinal Cord Injury

*
The Spinal Cord Injury market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinal Cord Injury pipeline products will significantly revolutionize the Spinal Cord Injury market dynamics.

Spinal Cord Injury Overview

A spinal cord injury (SCI) refers to damage to the spinal cord that results in a loss of function, sensation, or mobility. It can occur due to trauma, such as accidents or falls, or non-traumatic causes like infections or diseases. The severity of an SCI depends on factors such as the location and extent of the injury.

Get a Free sample for the Spinal Cord Injury Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/spinal-cord-injury-market [https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Spinal Cord Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Spinal Cord Injury Epidemiology Segmentation:

The Spinal Cord Injury market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Spinal Cord Injury

*
Prevalent Cases of Spinal Cord Injury by severity

*
Gender-specific Prevalence of Spinal Cord Injury

*
Diagnosed Cases of Episodic and Chronic Spinal Cord Injury

Download the report to understand which factors are driving Spinal Cord Injury epidemiology trends @ Spinal Cord Injury Epidemiology Forecast [https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Spinal Cord Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Cord Injury market or expected to get launched during the study period. The analysis covers Spinal Cord Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinal Cord Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Spinal Cord Injury Therapies and Key Companies

*
Allogeneic stem cell therapy: Athersys

*
OLT1177: Olatec Therapeutics

*
ALMB0166: AlaMab therapeutics

*
AXER-204: ReNetX Bio

*
FAB117-HC: Histocell

*
AST-OPC1: Lineage Cell Therapeutics

*
Elezanumab: AbbVie

*
MT 3921: Mitsubishi Tanabe Pharma

*
PMZ-1620: Pharmazz

*
ES 135: Eusol Biotech

*
KP-100IT: Kringle Pharma

*
NVG-291: NervGen Pharma

*
Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation

*
Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc

Discover more about therapies set to grab major Spinal Cord Injury market share @ Spinal Cord Injury Treatment Landscape [https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Spinal Cord Injury Market Strengths

*
Both universities and industries are coming up with better approaches aiming towards development of a novel therapy

*
Advances in understanding of Spinal Cord Injury pathophysiology over recent years has however led to a surge of clinical trials

Spinal Cord Injury Market Opportunities

*
Recent continuous efforts in basic and clinical research are creating new path to regenerative medicine for Spinal Cord Injury

*
Absence of an effective therapy targeting symptoms and complications associated with Spinal Cord Injury

Scope of the Spinal Cord Injury Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Spinal Cord Injury Companies: Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others

*
Key Spinal Cord Injury Therapies: Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, and others

*
Spinal Cord Injury Therapeutic Assessment: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies

*
Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Spinal Cord Injury Unmet Needs, KOL's views, Analyst's views, Spinal Cord Injury Market Access and Reimbursement

To know more about Spinal Cord Injury companies working in the treatment market, visit @ Spinal Cord Injury Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Spinal Cord Injury Market Report Introduction

2. Executive Summary for Spinal Cord Injury

3. SWOT analysis of Spinal Cord Injury

4. Spinal Cord Injury Patient Share (%) Overview at a Glance

5. Spinal Cord Injury Market Overview at a Glance

6. Spinal Cord Injury Disease Background and Overview

7. Spinal Cord Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Spinal Cord Injury

9. Spinal Cord Injury Current Treatment and Medical Practices

10. Spinal Cord Injury Unmet Needs

11. Spinal Cord Injury Emerging Therapies

12. Spinal Cord Injury Market Outlook

13. Country-Wise Spinal Cord Injury Market Analysis (2020-2034)

14. Spinal Cord Injury Market Access and Reimbursement of Therapies

15. Spinal Cord Injury Market Drivers

16. Spinal Cord Injury Market Barriers

17. Spinal Cord Injury Appendix

18. Spinal Cord Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spinal-cord-injury-market-growth-momentum-across-7mm-to-2034-delveinsight-kringle-pharma-neuroplast-abbvie-mitsubishi-tanabe-pharma-lineage-cell-therapeutics-nervgen-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.